In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 2030
In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)—Global Forecast to 2030
The global in vitro diagnostics market is expected to register a CAGR of 4.6% from 2023 to 2030 to reach $130.1 billion by 2030.
The growth of the global in vitro diagnostics market is mainly attributed to the rising prevalence of chronic diseases coupled with the increasing geriatric population, rising prevalence of acute and chronic infectious diseases, increasing funding for research activities, growing awareness regarding early disease diagnosis, growing demand for point-of-care (POC) diagnostics and rapid diagnosis, rising healthcare expenditure, and increasing funding for research activities. Moreover, the inclination of emerging economies toward personalized medicine and advancements in genomics & proteomics offer significant growth opportunities for the players operating in this market.
Based on offering, the reagents & kits segment is expected to grow with the fastest growth during the forecast period owing to its advantages as it can detect several markers simultaneously, which is useful for detecting complex diseases. Its technological superiority and the ability to facilitate chemical reactions further support the growth of this segment.
Based on the technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the market. The largest share of the segment attributed to its improved specificity, cost-savings and enhanced throughput when automated, minimizing the false positive test results by targeting specific molecules, as well as improved diagnosis of infections such as orthopedic infections.
Based on diagnostic approach, the laboratory testing segment is expected to account for the largest share of the market. Lab testing is a traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing. Factors such as low costs of tests, highly sensitive analyzers, more accuracy and reliability, and accessibility & availability of multiple IVD tests support the largest share of the segment.
Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the global in vitro diagnostics (IVD) market owing to the high prevalence of infectious diseases, government initiatives to promote awareness and testing, and emerging outbreaks of infectious diseases around the world.
Based on end user, the hospitals & clinics segment is expected to grow with the highest CAGR during the forecast period. Patient inflows at hospitals & clinics and subsequent increase in the volume of testing carried out in hospitals and clinics due to the outbreak of COVID-19 support the growth of this segment.
An in-depth analysis of the geographical scenario of the global in-vitro diagnostics (IVD) market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the IVD market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The high prevalence of chronic and infectious diseases, high awareness regarding early disease diagnosis, high adoption of advanced diagnostic products, and presence of funding coupled with novel developments in diagnostic technologies support the large share of this market.
The key players operating in the global in-vitro diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioM?rieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).
Scope of the Report:
Global In Vitro Diagnostics Market Assessment—by Offering
Global In Vitro Diagnostics Market Assessment—by Application
(Other infectious diseases include congenital infections, meningitis, norovirus (stomach flu), hand, foot, and mouth disease (HFMD), and pertussis).
Global In Vitro Diagnostics Market Assessment—by Diagnostic Approach
Global In vitro Diagnostics Market Assessment—by Geography
The global in vitro diagnostics market is expected to register a CAGR of 4.6% from 2023 to 2030 to reach $130.1 billion by 2030.
The growth of the global in vitro diagnostics market is mainly attributed to the rising prevalence of chronic diseases coupled with the increasing geriatric population, rising prevalence of acute and chronic infectious diseases, increasing funding for research activities, growing awareness regarding early disease diagnosis, growing demand for point-of-care (POC) diagnostics and rapid diagnosis, rising healthcare expenditure, and increasing funding for research activities. Moreover, the inclination of emerging economies toward personalized medicine and advancements in genomics & proteomics offer significant growth opportunities for the players operating in this market.
Based on offering, the reagents & kits segment is expected to grow with the fastest growth during the forecast period owing to its advantages as it can detect several markers simultaneously, which is useful for detecting complex diseases. Its technological superiority and the ability to facilitate chemical reactions further support the growth of this segment.
Based on the technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the market. The largest share of the segment attributed to its improved specificity, cost-savings and enhanced throughput when automated, minimizing the false positive test results by targeting specific molecules, as well as improved diagnosis of infections such as orthopedic infections.
Based on diagnostic approach, the laboratory testing segment is expected to account for the largest share of the market. Lab testing is a traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing. Factors such as low costs of tests, highly sensitive analyzers, more accuracy and reliability, and accessibility & availability of multiple IVD tests support the largest share of the segment.
Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the global in vitro diagnostics (IVD) market owing to the high prevalence of infectious diseases, government initiatives to promote awareness and testing, and emerging outbreaks of infectious diseases around the world.
Based on end user, the hospitals & clinics segment is expected to grow with the highest CAGR during the forecast period. Patient inflows at hospitals & clinics and subsequent increase in the volume of testing carried out in hospitals and clinics due to the outbreak of COVID-19 support the growth of this segment.
An in-depth analysis of the geographical scenario of the global in-vitro diagnostics (IVD) market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the IVD market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The high prevalence of chronic and infectious diseases, high awareness regarding early disease diagnosis, high adoption of advanced diagnostic products, and presence of funding coupled with novel developments in diagnostic technologies support the large share of this market.
The key players operating in the global in-vitro diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioM?rieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).
Scope of the Report:
Global In Vitro Diagnostics Market Assessment—by Offering
- Reagents & Kits
- Instruments
- Software & Services
- Molecular Diagnostics
- Polymerase Chain Reaction (PCR)
- Hybridization
- Isothermal Nucleic Acid Amplification Technology
- DNA Sequencing & Next-generation Sequencing
- Microarrays
- Mass Spectrometry
- Other Molecular Diagnostic Technologies
- Point of Care (POC) Diagnostics
- Lateral Flow Assays/Rapid Tests
- POC Molecular Diagnostics
- Other PoC Products
- Immunoassay/Immunochemistry
- Enzyme-linked Immunosorbent Assays (ELISA)
- Enzyme-linked Immunospot Assays (ELISPOT)
- Western Blotting
- Radioimmunoassay
- Biochemistry/Clinical Chemistry
- Metabolic Panel
- Electrolyte Panel
- Liver Panel
- Lipid Profile
- Renal Profile
- Thyroid Function Panel
- Whole Blood Glucose Monitoring
- Microbiology
- Hematology
- Coagulation/Hemostasis
- Urinalysis
- Other IVD Technologies
Global In Vitro Diagnostics Market Assessment—by Application
- Infectious Diseases
- COVID-19 Testing
- Sexually Transmitted Diseases (STD) Testing
- Healthcare-associated Infections (HAIs)
- Hepatitis
- HIV
- Tropical Diseases
- Respiratory Infections (Excluding Influenza)
- Influenza
- Other Infectious Diseases
- Oncology
- Diabetes
- Cardiology
- Nephrology
- Autoimmune Disorders
- Other Applications
(Other infectious diseases include congenital infections, meningitis, norovirus (stomach flu), hand, foot, and mouth disease (HFMD), and pertussis).
Global In Vitro Diagnostics Market Assessment—by Diagnostic Approach
- Laboratory Testing
- OTC/Self-testing
- Point-of-Care Testing
- Diagnostic Laboratories
- Hospitals & Clinics
- Home Healthcare
- Other End Users
Global In vitro Diagnostics Market Assessment—by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Switzerland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Saudi Arabia
- Rest of Middle East
- Africa
- South Africa
- Rest of Africa
1. OVERVIEW
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitation
1.4. Key Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews With Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Market Share Analysis
2.3.3. Growth Forecast Approach
2.4. Assumptions for the Study
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1. Overview
4.2. Drivers
4.2.1. Rising Prevalence of Chronic Diseases Coupled With the Increasing Geriatric Population
4.2.2. Rising Prevalence of Infectious Diseases
4.2.3. Growing Demand for Point-of-Care (PoC) and Rapid Diagnostics
4.2.4. Rising Awareness Regarding Early Disease Diagnosis
4.2.5. Rising Healthcare Expenditures
4.2.6. Increasing Funding for Research Activities
4.3. Restraints
4.3.1. Stringent Technical Requirements and Regulatory Processes for High/Moderate-Complexity Tests
4.3.2. Variance in Test Results Observed in Rapid IVD Tests
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Increasing Inclination Toward Personalized Medicine
4.4.3. Advancements in Genomics and Proteomics
4.5. Challenges
4.5.1. Evolving Regulatory Landscape
4.6. Technology Trends
4.6.1. Integration of Artificial Intelligence & Machine Learning in Molecular Diagnostics
4.6.2. Development of Smartphone-based Detection Platforms for Rapid Diagnostic Tests
4.6.3. Increasing Applications of Next-generation Sequencing Technology
5. IN VITRO DIAGNOSTICS (IVD) MARKET: REGULATORY ANALYSIS
5.1. Overview
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.4. Asia-Pacific
5.4.1. China
5.4.2. Japan
5.4.3. India
5.5. Latin America
5.6. Middle East
6. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT—BY OFFERING
6.1. Overview
6.2. Reagents & Kits
6.3. Systems
6.4. Software & Services
7. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT—BY TECHNOLOGY
7.1. Overview
7.2. Molecular Diagnostics
7.2.1. Polymerase Chain Reaction (PCR)
7.2.2. Hybridization
7.2.3. Isothermal Nucleic Acid Amplification Technology
7.2.4. DNA Sequencing & Next-Generation Sequencing
7.2.5. Microarrays
7.2.6. Mass Spectrometry
7.2.7. Other Molecular Diagnostic Technologies
7.3. Point-of-Care (PoC) Diagnostics
7.3.1. Lateral Flow Assays/Rapid Tests
7.3.2. PoC Molecular Diagnostics
7.3.3. Other PoC Products
7.4. Immunoassay/Immunochemistry
7.4.1. Enzyme-linked Immunosorbent Assays (ELISA)
7.4.2. Enzyme-linked Immunospot Assays (ELISPOT)
7.4.3. Western Blotting
7.4.4. Radioimmunoassay
7.5. Biochemistry/Clinical Chemistry
7.5.1. Metabolic Panels
7.5.2. Electrolyte Panels
7.5.3. Liver Panels
7.5.4. Lipid Profiles
7.5.5. Renal Profiles
7.5.6. Thyroid Function Panels
7.6. Whole Blood Glucose Monitoring
7.7. Microbiology
7.8. Hematology
7.9. Coagulation/Hemostasis
7.10. Urinalysis
7.11. Other IVD Technologies
8. IN VITRO DIAGNOSTIC (IVD) MARKET—BY APPLICATION
8.1. Overview
8.2. Infectious Diseases
8.2.1. COVID-19 Testing
8.2.2. Sexually Transmitted Diseases (STD) Testing
8.2.3. Healthcare-associated Infections (HAIs)
8.2.4. Hepatitis
8.2.5. HIV
8.2.6. Tropical Diseases
8.2.7. Influenza
8.2.8. Respiratory Infections (Excluding Influenza)
8.2.9. Other Infectious Diseases
8.3. Oncology
8.4. Diabetes
8.5. Cardiology
8.6. Nephrology
8.7. Autoimmune Disorders
8.8. Other Applications
9. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT—BY DIAGNOSTIC APPROACH
9.1. Overview
9.2. Laboratory Testing
9.3. OTC/Self Testing
9.4. Point-of-Care Testing
10. IN VITRO DIAGNOSTICS (IVD) MARKET—BY END USER
10.1. Overview
10.2. Hospitals & Clinics
10.3. Diagnostic Laboratories
10.4. Home Healthcare
10.5. Other End Users
11. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT, BY GEOGRAPHY
11.1. Overview
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Switzerland
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. South Korea
11.4.5. Australia
11.4.6. Rest of Asia-Pacific
11.5. Latin America
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Argentina
11.5.4. Rest of Latin America
11.6. Middle East
11.6.1. Saudi Arabia
11.6.2. Rest of Middle East
11.7. Africa
11.7.1. South Africa
11.7.2. Rest of Africa
12. COMPETITIVE LANDSCAPE
12.1. Overview
12.2. Key Growth Strategies
12.3. Competitive Dashboard
12.3.1. Industry Leaders
12.3.2. Market Differentiators
12.3.3. Vanguards
12.3.4. Emerging Companies
12.4. Vendor Market Positioning
12.5. Market Share Analysis (2022: Top 15 Players)
12.5.1. F. Hoffman-La Roche Ltd. (Switzerland)
12.5.2. Abbott Laboratories (U.S.)
12.5.3. Danaher Corporation (U.S)
12.5.4. Siemens Healthineers AG (Germany)
12.5.5. Thermo Fisher Scientific Inc. (U.S.)
13. COMPANY PROFILES
13.1. Abbott Laboratories
13.2. Becton, Dickinson and Company
13.3. biom?rieux S.A.
13.4. Danaher Corporation
13.5. F. Hoffman-La Roche Ltd
13.6. Qiagen N.V.
13.7. Siemens Healthineers AG (A Subsidiary of Siemens AG)
13.8. Thermo Fisher Scientific Inc.
13.9. Bio-Rad Laboratories, Inc.
13.10. Wama Diagnostica
13.11. lllumina, Inc.
13.12. Wiener Laboratories SAIC
13.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
13.14. QuidelOrtho Corporation
13.15. Agilent Technologies, Inc.
13.16. DiaSorin S.p.A.
14. APPENDIX
14.1. Available Customization
14.2. Related Reports
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitation
1.4. Key Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews With Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Market Share Analysis
2.3.3. Growth Forecast Approach
2.4. Assumptions for the Study
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1. Overview
4.2. Drivers
4.2.1. Rising Prevalence of Chronic Diseases Coupled With the Increasing Geriatric Population
4.2.2. Rising Prevalence of Infectious Diseases
4.2.3. Growing Demand for Point-of-Care (PoC) and Rapid Diagnostics
4.2.4. Rising Awareness Regarding Early Disease Diagnosis
4.2.5. Rising Healthcare Expenditures
4.2.6. Increasing Funding for Research Activities
4.3. Restraints
4.3.1. Stringent Technical Requirements and Regulatory Processes for High/Moderate-Complexity Tests
4.3.2. Variance in Test Results Observed in Rapid IVD Tests
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Increasing Inclination Toward Personalized Medicine
4.4.3. Advancements in Genomics and Proteomics
4.5. Challenges
4.5.1. Evolving Regulatory Landscape
4.6. Technology Trends
4.6.1. Integration of Artificial Intelligence & Machine Learning in Molecular Diagnostics
4.6.2. Development of Smartphone-based Detection Platforms for Rapid Diagnostic Tests
4.6.3. Increasing Applications of Next-generation Sequencing Technology
5. IN VITRO DIAGNOSTICS (IVD) MARKET: REGULATORY ANALYSIS
5.1. Overview
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.4. Asia-Pacific
5.4.1. China
5.4.2. Japan
5.4.3. India
5.5. Latin America
5.6. Middle East
6. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT—BY OFFERING
6.1. Overview
6.2. Reagents & Kits
6.3. Systems
6.4. Software & Services
7. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT—BY TECHNOLOGY
7.1. Overview
7.2. Molecular Diagnostics
7.2.1. Polymerase Chain Reaction (PCR)
7.2.2. Hybridization
7.2.3. Isothermal Nucleic Acid Amplification Technology
7.2.4. DNA Sequencing & Next-Generation Sequencing
7.2.5. Microarrays
7.2.6. Mass Spectrometry
7.2.7. Other Molecular Diagnostic Technologies
7.3. Point-of-Care (PoC) Diagnostics
7.3.1. Lateral Flow Assays/Rapid Tests
7.3.2. PoC Molecular Diagnostics
7.3.3. Other PoC Products
7.4. Immunoassay/Immunochemistry
7.4.1. Enzyme-linked Immunosorbent Assays (ELISA)
7.4.2. Enzyme-linked Immunospot Assays (ELISPOT)
7.4.3. Western Blotting
7.4.4. Radioimmunoassay
7.5. Biochemistry/Clinical Chemistry
7.5.1. Metabolic Panels
7.5.2. Electrolyte Panels
7.5.3. Liver Panels
7.5.4. Lipid Profiles
7.5.5. Renal Profiles
7.5.6. Thyroid Function Panels
7.6. Whole Blood Glucose Monitoring
7.7. Microbiology
7.8. Hematology
7.9. Coagulation/Hemostasis
7.10. Urinalysis
7.11. Other IVD Technologies
8. IN VITRO DIAGNOSTIC (IVD) MARKET—BY APPLICATION
8.1. Overview
8.2. Infectious Diseases
8.2.1. COVID-19 Testing
8.2.2. Sexually Transmitted Diseases (STD) Testing
8.2.3. Healthcare-associated Infections (HAIs)
8.2.4. Hepatitis
8.2.5. HIV
8.2.6. Tropical Diseases
8.2.7. Influenza
8.2.8. Respiratory Infections (Excluding Influenza)
8.2.9. Other Infectious Diseases
8.3. Oncology
8.4. Diabetes
8.5. Cardiology
8.6. Nephrology
8.7. Autoimmune Disorders
8.8. Other Applications
9. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT—BY DIAGNOSTIC APPROACH
9.1. Overview
9.2. Laboratory Testing
9.3. OTC/Self Testing
9.4. Point-of-Care Testing
10. IN VITRO DIAGNOSTICS (IVD) MARKET—BY END USER
10.1. Overview
10.2. Hospitals & Clinics
10.3. Diagnostic Laboratories
10.4. Home Healthcare
10.5. Other End Users
11. IN VITRO DIAGNOSTICS (IVD) MARKET ASSESSMENT, BY GEOGRAPHY
11.1. Overview
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Switzerland
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. South Korea
11.4.5. Australia
11.4.6. Rest of Asia-Pacific
11.5. Latin America
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Argentina
11.5.4. Rest of Latin America
11.6. Middle East
11.6.1. Saudi Arabia
11.6.2. Rest of Middle East
11.7. Africa
11.7.1. South Africa
11.7.2. Rest of Africa
12. COMPETITIVE LANDSCAPE
12.1. Overview
12.2. Key Growth Strategies
12.3. Competitive Dashboard
12.3.1. Industry Leaders
12.3.2. Market Differentiators
12.3.3. Vanguards
12.3.4. Emerging Companies
12.4. Vendor Market Positioning
12.5. Market Share Analysis (2022: Top 15 Players)
12.5.1. F. Hoffman-La Roche Ltd. (Switzerland)
12.5.2. Abbott Laboratories (U.S.)
12.5.3. Danaher Corporation (U.S)
12.5.4. Siemens Healthineers AG (Germany)
12.5.5. Thermo Fisher Scientific Inc. (U.S.)
13. COMPANY PROFILES
13.1. Abbott Laboratories
13.2. Becton, Dickinson and Company
13.3. biom?rieux S.A.
13.4. Danaher Corporation
13.5. F. Hoffman-La Roche Ltd
13.6. Qiagen N.V.
13.7. Siemens Healthineers AG (A Subsidiary of Siemens AG)
13.8. Thermo Fisher Scientific Inc.
13.9. Bio-Rad Laboratories, Inc.
13.10. Wama Diagnostica
13.11. lllumina, Inc.
13.12. Wiener Laboratories SAIC
13.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
13.14. QuidelOrtho Corporation
13.15. Agilent Technologies, Inc.
13.16. DiaSorin S.p.A.
14. APPENDIX
14.1. Available Customization
14.2. Related Reports
LIST OF TABLES
Table 1 Global IVD Market: Impact Analysis of Market Drivers (2023–2030)
Table 2 Number of People With Diabetes Aged 20–79, by Region, 2021 Vs. 2030 Vs. 2045 (In Thousands)
Table 3 Population Aged 65 Years Or Above, by Region, 2019 Vs. 2030 Vs. 2050 (In Millions)
Table 4 Estimated Number of New Cancer Cases, by Type (2020 Vs. 2030)
Table 5 HIV Statistics (2021)
Table 6 Healthcare Expenditure As A Percentage of GDP, by Country (2014 Vs. 2019)
Table 7 Healthcare Expenditure, by Country (2020, 2021, and 2022)
Table 8 Global IVD Market: Impact Analysis of Market Restraints (2023–2030)
Table 9 Requirements for CLIA-Waived and Moderate/High-complexity PoC Molecular Diagnostic Tests
Table 10 Global IVD Market: Impact Analysis of Market Opportunities (2023–2030)
Table 11 Emerging Countries: Percentage of Urban Population (2021 Vs. 2025 Vs. 2050)
Table 12 Biomarkers and Corresponding Targeted Therapies Currently Available
Table 13 Clinical Applications of Genomics and Proteomics in Infectious Disease Diagnosis
Table 14 Global IVD Market: Impact Analysis of Market Challenges (2023–2030)
Table 15 Regulatory Authorities Governing In Vitro Diagnostics, by Country
Table 16 Some of the Emergency Use Authorizations (EUAs) Granted for IVD During the COVID-19 Pandemic
Table 17 Global In Vitro Diagnostics (IVD) Market, by Offering, 2021–2030 (USD Million)
Table 18 Global IVD Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 19 Global IVD Systems Market, by Country/Region, 2021–2030 (USD Million)
Table 20 Global IVD Software & Services Market, by Country/Region, 2021–2030 (USD Million)
Table 21 Global In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 22 Global Molecular Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 23 Global Molecular Diagnostics Market, by Country/Region, 2021-2030 (USD Million)
Table 24 Key Companies Offering PCR Products
Table 25 Global Polymerase Chain Reaction Market, by Country/Region, 2021-2030 (USD Million)
Table 26 Global Hybridization Market, by Country/Region, 2021-2030 (USD Million)
Table 27 Key Companies Offering Isothermal Nucleic Acid Amplification Products
Table 28 Global Isothermal Nucleic Acid Amplification Market, by Country/Region, 2021–2030 (USD Million)
Table 29 Key Companies Offering DNA Sequencing & Next-generation Sequencing Products
Table 30 Global DNA Sequencing and Next-Generation Sequencing Market, by Country/Region, 2021-2030 (USD Million)
Table 31 Key Companies Offering Microarray Products
Table 32 Global Microarrays Market, by Country/Region, 2021–2030 (USD Million)
Table 33 Global Mass Spectrometry Market, by Country/Region, 2021-2030 (USD Million)
Table 34 Other Molecular Diagnostic Technologies Market, by Country/Region, 2021-2030 (USD Million)
Table 35 Global Point-of-Care (PoC) Diagnostics Market, by Technology, 2021-2030, (USD Million)
Table 36 Global Point-of-Care (PoC) Diagnostics Market, by Country/Region, 2021-2030, (USD Million)
Table 37 Global Lateral Flow Assays/Rapid Tests Market, by 2021-2030 (USD Million)
Table 38 Global PoC Molecular Diagnostics Market, 2021-2030 (USD Million)
Table 39 Other PoC Products Market, by Country/Region, 2021-2030 (USD Million)
Table 40 Global Immunoassay/Immunochemistry Market, by Type, 2021–2030 (USD Million)
Table 41 Global Immunoassay/Immunochemistry Market, by Country/Region, 2021–2030 (USD Million)
Table 42 Global Enzyme-Linked Immunosorbent Assays (ELISA) Market, by Country/Region, 2021–2030 (USD Million)
Table 43 ELISPOT Vs. Conventional ELISA
Table 44 Global Enzyme-Linked Immunospot Assays (ELISPOT) Market, by Country/Region, 2021–2030 (USD Million)
Table 45 Global Western Blotting Market, by Country/Region, 2021–2030 (USD Million)
Table 46 Global Radioimmunoassay Market, by Country/Region, 2021–2030 (USD Million)
Table 47 Global Biochemistry/Clinical Chemistry Market, by Type, 2021–2030 (USD Million)
Table 48 Global Metabolic Panels Market, by Country/Region, 2021–2030 (USD Million)
Table 49 Global Electrolyte Panels Market, by Country/Region, 2021-2030, (USD Million)
Table 50 Global Liver Panels Market, by Country/Region, 2021-2030, (USD Million)
Table 51 Global Lipid Profiles Market, by Country/Region, 2021-2030 (USD Million)
Table 52 Global Renal Profiles Market, by Country/Region, 2021-2030 (USD Million)
Table 53 Global Thyroid Function Panels Market, by Country/Region, 2021-2030 (USD Million)
Table 54 Number of People With Diabetes Aged 20–79 Years, by Region, 2019 Vs. 2030 Vs. 2045 (In Million)
Table 55 Global Whole Blood Glucose Monitoring Market, by Country/Region, 2021–2030 (USD Million)
Table 56 Key Companies Offering Microbiology-based IVD Products
Table 57 Global Microbiology Market, by Country/Region, 2021–2030 (USD Million)
Table 58 Key Companies Offering Hematology Products
Table 59 Global Hematology Market, by Country/Region, 2021–2030 (USD Million)
Table 60 Key Companies Offering Coagulation and Hemostasis Products
Table 61 Global Coagulation and Hemostasis Market, by Country/Region, 2021–2030 (USD Million)
Table 62 Key Companies Offering Urinalysis Products
Table 63 Global Urinalysis Market, by Country/Region, 2021–2030 (USD Million)
Table 64 Global Other IVD Technologies Market, by Country/Region, 2021–2030 (USD Million)
Table 65 Global In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 66 Global In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 67 Global In Vitro Diagnostics Market for Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 68 Recently Launched and Approved Rapid Diagnostic Tests for COVID-19 Detection
Table 69 Global Invitro Diagnostics Market for COVID-19 Testing, by Country/Region, 2021–2030 (USD Million)
Table 70 Global In Vitro Diagnostics Market for Sexually Transmitted Diseases (STD) Testing, by Country/Region, 2021–2030 (USD Million)
Table 71 Global In Vitro Diagnostics Market for Healthcare-associated Infections (HAIs), by Country/Region, 2021–2030 (USD Million)
Table 72 Global In Vitro Diagnostics Market for Hepatitis, by Country/Region, 2021–2030 (USD Million)
Table 73 Global Prevalence of HIV, by Region (2020)
Table 74 Global In Vitro Diagnostics Market for HIV, by Country/Region, 2021–2030 (USD Million)
Table 75 Global In Vitro Diagnostics Market for Tropical Diseases, by Country/Region, 2021–2030 (USD Million)
Table 76 Global In Vitro Diagnostics Market for Influenza, by Country/Region, 2021–2030 (USD Million)
Table 77 Global In Vitro Diagnostics Market for Respiratory Infections, by Country/Region, 2021–2030 (USD Million)
Table 78 Global In Vitro Diagnostics Market for Other Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 79 Global In Vitro Diagnostics Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 80 Number of People With Diabetes Aged 20–79 Years, by Region, 2021 Vs. 2030 Vs. 2045 (In Million)
Table 81 Global In Vitro Diagnostics Market for Diabetes, by Country/Region, 2021–2030 (USD Million)
Table 82 Global In Vitro Diagnostics Market for Cardiology, by Country/Region, 2021–2030 (USD Million)
Table 83 Global In Vitro Diagnostics Market for Nephrology, by Country/Region, 2021–2030 (USD Million)
Table 84 Global In Vitro Diagnostics Market for Autoimmune Disorders, by Country/Region, 2021–2030 (USD Million)
Table 85 Global In Vitro Diagnostics Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 86 Global In Vitro Diagnostics Market, by Diagnostic Approach 2021-2030 (USD Million)
Table 87 Global In Vitro Diagnostics Market for Laboratory Testing, by Country/Region, 2021-2030 (USD Million)
Table 88 Global In Vitro Diagnostics Market for OTC/Self-testing, by Country/Region, 2021–2030 (USD Million)
Table 89 Global In Vitro Diagnostics Market for Point-of-Care Testing, by Country/Region, 2021–2030 (USD Million)
Table 90 Global In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 91 Global In Vitro Diagnostics Market for Hospitals & Clinics, by Country/Region, 2021-2030 (USD Million)
Table 92 Global In Vitro Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021-2030 (USD Million)
Table 93 Global In Vitro Diagnostics Market for Home Healthcare, by Country/Region, 2021-2030 (USD Million)
Table 94 Global In Vitro Diagnostics Market for Other End Users, by Country/Region, 2021-2030 (USD Million)
Table 95 Global In Vitro Diagnostics Market, by Country/Region, 2021 Vs. 2030 (USD Million)
Table 96 North America: In Vitro Diagnostics Market, by Country, 2021–2030 (USD Million)
Table 97 North America: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 98 North America: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 99 North America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 100 North America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
...
Table 1 Global IVD Market: Impact Analysis of Market Drivers (2023–2030)
Table 2 Number of People With Diabetes Aged 20–79, by Region, 2021 Vs. 2030 Vs. 2045 (In Thousands)
Table 3 Population Aged 65 Years Or Above, by Region, 2019 Vs. 2030 Vs. 2050 (In Millions)
Table 4 Estimated Number of New Cancer Cases, by Type (2020 Vs. 2030)
Table 5 HIV Statistics (2021)
Table 6 Healthcare Expenditure As A Percentage of GDP, by Country (2014 Vs. 2019)
Table 7 Healthcare Expenditure, by Country (2020, 2021, and 2022)
Table 8 Global IVD Market: Impact Analysis of Market Restraints (2023–2030)
Table 9 Requirements for CLIA-Waived and Moderate/High-complexity PoC Molecular Diagnostic Tests
Table 10 Global IVD Market: Impact Analysis of Market Opportunities (2023–2030)
Table 11 Emerging Countries: Percentage of Urban Population (2021 Vs. 2025 Vs. 2050)
Table 12 Biomarkers and Corresponding Targeted Therapies Currently Available
Table 13 Clinical Applications of Genomics and Proteomics in Infectious Disease Diagnosis
Table 14 Global IVD Market: Impact Analysis of Market Challenges (2023–2030)
Table 15 Regulatory Authorities Governing In Vitro Diagnostics, by Country
Table 16 Some of the Emergency Use Authorizations (EUAs) Granted for IVD During the COVID-19 Pandemic
Table 17 Global In Vitro Diagnostics (IVD) Market, by Offering, 2021–2030 (USD Million)
Table 18 Global IVD Kits & Reagents Market, by Country/Region, 2021–2030 (USD Million)
Table 19 Global IVD Systems Market, by Country/Region, 2021–2030 (USD Million)
Table 20 Global IVD Software & Services Market, by Country/Region, 2021–2030 (USD Million)
Table 21 Global In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 22 Global Molecular Diagnostics Market, by Type, 2021–2030 (USD Million)
Table 23 Global Molecular Diagnostics Market, by Country/Region, 2021-2030 (USD Million)
Table 24 Key Companies Offering PCR Products
Table 25 Global Polymerase Chain Reaction Market, by Country/Region, 2021-2030 (USD Million)
Table 26 Global Hybridization Market, by Country/Region, 2021-2030 (USD Million)
Table 27 Key Companies Offering Isothermal Nucleic Acid Amplification Products
Table 28 Global Isothermal Nucleic Acid Amplification Market, by Country/Region, 2021–2030 (USD Million)
Table 29 Key Companies Offering DNA Sequencing & Next-generation Sequencing Products
Table 30 Global DNA Sequencing and Next-Generation Sequencing Market, by Country/Region, 2021-2030 (USD Million)
Table 31 Key Companies Offering Microarray Products
Table 32 Global Microarrays Market, by Country/Region, 2021–2030 (USD Million)
Table 33 Global Mass Spectrometry Market, by Country/Region, 2021-2030 (USD Million)
Table 34 Other Molecular Diagnostic Technologies Market, by Country/Region, 2021-2030 (USD Million)
Table 35 Global Point-of-Care (PoC) Diagnostics Market, by Technology, 2021-2030, (USD Million)
Table 36 Global Point-of-Care (PoC) Diagnostics Market, by Country/Region, 2021-2030, (USD Million)
Table 37 Global Lateral Flow Assays/Rapid Tests Market, by 2021-2030 (USD Million)
Table 38 Global PoC Molecular Diagnostics Market, 2021-2030 (USD Million)
Table 39 Other PoC Products Market, by Country/Region, 2021-2030 (USD Million)
Table 40 Global Immunoassay/Immunochemistry Market, by Type, 2021–2030 (USD Million)
Table 41 Global Immunoassay/Immunochemistry Market, by Country/Region, 2021–2030 (USD Million)
Table 42 Global Enzyme-Linked Immunosorbent Assays (ELISA) Market, by Country/Region, 2021–2030 (USD Million)
Table 43 ELISPOT Vs. Conventional ELISA
Table 44 Global Enzyme-Linked Immunospot Assays (ELISPOT) Market, by Country/Region, 2021–2030 (USD Million)
Table 45 Global Western Blotting Market, by Country/Region, 2021–2030 (USD Million)
Table 46 Global Radioimmunoassay Market, by Country/Region, 2021–2030 (USD Million)
Table 47 Global Biochemistry/Clinical Chemistry Market, by Type, 2021–2030 (USD Million)
Table 48 Global Metabolic Panels Market, by Country/Region, 2021–2030 (USD Million)
Table 49 Global Electrolyte Panels Market, by Country/Region, 2021-2030, (USD Million)
Table 50 Global Liver Panels Market, by Country/Region, 2021-2030, (USD Million)
Table 51 Global Lipid Profiles Market, by Country/Region, 2021-2030 (USD Million)
Table 52 Global Renal Profiles Market, by Country/Region, 2021-2030 (USD Million)
Table 53 Global Thyroid Function Panels Market, by Country/Region, 2021-2030 (USD Million)
Table 54 Number of People With Diabetes Aged 20–79 Years, by Region, 2019 Vs. 2030 Vs. 2045 (In Million)
Table 55 Global Whole Blood Glucose Monitoring Market, by Country/Region, 2021–2030 (USD Million)
Table 56 Key Companies Offering Microbiology-based IVD Products
Table 57 Global Microbiology Market, by Country/Region, 2021–2030 (USD Million)
Table 58 Key Companies Offering Hematology Products
Table 59 Global Hematology Market, by Country/Region, 2021–2030 (USD Million)
Table 60 Key Companies Offering Coagulation and Hemostasis Products
Table 61 Global Coagulation and Hemostasis Market, by Country/Region, 2021–2030 (USD Million)
Table 62 Key Companies Offering Urinalysis Products
Table 63 Global Urinalysis Market, by Country/Region, 2021–2030 (USD Million)
Table 64 Global Other IVD Technologies Market, by Country/Region, 2021–2030 (USD Million)
Table 65 Global In Vitro Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 66 Global In Vitro Diagnostics Market for Infectious Diseases, by Type, 2021–2030 (USD Million)
Table 67 Global In Vitro Diagnostics Market for Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 68 Recently Launched and Approved Rapid Diagnostic Tests for COVID-19 Detection
Table 69 Global Invitro Diagnostics Market for COVID-19 Testing, by Country/Region, 2021–2030 (USD Million)
Table 70 Global In Vitro Diagnostics Market for Sexually Transmitted Diseases (STD) Testing, by Country/Region, 2021–2030 (USD Million)
Table 71 Global In Vitro Diagnostics Market for Healthcare-associated Infections (HAIs), by Country/Region, 2021–2030 (USD Million)
Table 72 Global In Vitro Diagnostics Market for Hepatitis, by Country/Region, 2021–2030 (USD Million)
Table 73 Global Prevalence of HIV, by Region (2020)
Table 74 Global In Vitro Diagnostics Market for HIV, by Country/Region, 2021–2030 (USD Million)
Table 75 Global In Vitro Diagnostics Market for Tropical Diseases, by Country/Region, 2021–2030 (USD Million)
Table 76 Global In Vitro Diagnostics Market for Influenza, by Country/Region, 2021–2030 (USD Million)
Table 77 Global In Vitro Diagnostics Market for Respiratory Infections, by Country/Region, 2021–2030 (USD Million)
Table 78 Global In Vitro Diagnostics Market for Other Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 79 Global In Vitro Diagnostics Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 80 Number of People With Diabetes Aged 20–79 Years, by Region, 2021 Vs. 2030 Vs. 2045 (In Million)
Table 81 Global In Vitro Diagnostics Market for Diabetes, by Country/Region, 2021–2030 (USD Million)
Table 82 Global In Vitro Diagnostics Market for Cardiology, by Country/Region, 2021–2030 (USD Million)
Table 83 Global In Vitro Diagnostics Market for Nephrology, by Country/Region, 2021–2030 (USD Million)
Table 84 Global In Vitro Diagnostics Market for Autoimmune Disorders, by Country/Region, 2021–2030 (USD Million)
Table 85 Global In Vitro Diagnostics Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 86 Global In Vitro Diagnostics Market, by Diagnostic Approach 2021-2030 (USD Million)
Table 87 Global In Vitro Diagnostics Market for Laboratory Testing, by Country/Region, 2021-2030 (USD Million)
Table 88 Global In Vitro Diagnostics Market for OTC/Self-testing, by Country/Region, 2021–2030 (USD Million)
Table 89 Global In Vitro Diagnostics Market for Point-of-Care Testing, by Country/Region, 2021–2030 (USD Million)
Table 90 Global In Vitro Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 91 Global In Vitro Diagnostics Market for Hospitals & Clinics, by Country/Region, 2021-2030 (USD Million)
Table 92 Global In Vitro Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021-2030 (USD Million)
Table 93 Global In Vitro Diagnostics Market for Home Healthcare, by Country/Region, 2021-2030 (USD Million)
Table 94 Global In Vitro Diagnostics Market for Other End Users, by Country/Region, 2021-2030 (USD Million)
Table 95 Global In Vitro Diagnostics Market, by Country/Region, 2021 Vs. 2030 (USD Million)
Table 96 North America: In Vitro Diagnostics Market, by Country, 2021–2030 (USD Million)
Table 97 North America: In Vitro Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 98 North America: In Vitro Diagnostics Market, by Technology, 2021–2030 (USD Million)
Table 99 North America: In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2021–2030 (USD Million)
Table 100 North America: In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2021–2030 (USD Million)
...
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 8 Global in Vitro Diagnostic (IVD) Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global in Vitro Diagnostic Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global in Vitro Diagnostic Market, by Diagnostic Approach, 2023 Vs. 2030 (USD Million)
Figure 11 Global in Vitro Diagnostic Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Global IVD Market, by Geography
Figure 13 Factors Affecting Market Growth
Figure 14 U.S.: Medical and Health R&D Expenditure, 2016–2020 (USD Billion)
Figure 15 Global Biopharmaceutical R&D Expenditure, 2016–2028 (USD Billion)
Figure 16 USFDA Regulatory Pathways for IVD Kits
Figure 17 EU Regulatory Pathway - IVDR 2017/746
Figure 18 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
Figure 19 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 20 Global in Vitro Diagnostic Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 21 Global In Vitro Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 22 U.S.: Estimated Acute Hepatitis C Cases, 2011–2020
Figure 23 Estimated Number of New Cancer Cases, by Region, 2020–2040 (Million)
Figure 24 Total Number of Accredited Testing Laboratories (ISO/IEC 17025), 2016–2020
Figure 25 Prevalence of Diabetes Across the World (In Million)
Figure 26 Global In Vitro Diagnostics Market, by Diagnostic Approach 2023 Vs. 2030 (USD Million)
Figure 27 Benefits of Laboratory Testing Approach
Figure 28 Benefits of the Point-of-Care Testing Approach
Figure 29 Global In Vitro Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 30 Global In Vitro Diagnostics Market, by Region, 2023 Vs. 2030 (USD Million)
Figure 31 North America: Number of People Aged 65 Years and Above, 2015–2021 (Million)
Figure 32 North America: Per Capita Health Expenditure (USD), 2017–2021
Figure 33 North America: In Vitro Diagnostics Market Snapshot
Figure 34 Canada: Number of People Aged 65 and Above, 2018–2022 (Million)
Figure 35 Europe: Number of People Aged 65 and Above (In Million) (2015–2021)
Figure 36 Europe: In Vitro Diagnostics Market Snapshot
Figure 37 France: Percentage of Population Aged 65 Years and Above (2016–2021)
Figure 38 France: Prevalence of Chronic Diseases in People Aged 65 and Above (2020)
Figure 39 U.K: Number of Cancer Cases, 2010–2030 (Million)
Figure 40 U.K.: Number of Diabetes and Urogenital, Blood, and Endocrine Disease Cases – DALYS (Disability-Adjusted Life Years), 2017–2020 (Thousand)
Figure 41 U.K.: Number of People Diagnosed With Sexually Transmitted Infections, 2018–2020 (Thousand)
Figure 42 Prevalence of HAI in Healthcare-Associated Infections in Acute-Care Wards (2016–2021)
Figure 43 Italy: Ovarian Cancer Cases Diagnosed (2018–2020)
Figure 44 Number of HIV Tests Performed in Catalonia (Spain) (2014–2021)
Figure 45 Switzerland: Number of New Cancer Cases (2020–2040)
Figure 46 Switzerland: Number of People Aged 65 Years and Above (2017–2021)
Figure 47 Asia-Pacific: In Vitro Diagnostics Market Snapshot
Figure 48 Japan: Percentage Share of the Geriatric Population (Aged 65 Years And Above) (2015–2022)
Figure 49 Japan: New Cancer Cases Reported (2020–2040)
Figure 50 China: Independent Medical Laboratories Market, 2015–2021 (USD Million)
Figure 51 India: Number of People Aged 65 Years and Above, 2017–2021 (Million)
Figure 52 Latin America: In Vitro Diagnostics Market Snapshot
Figure 53 Brazil: Challenges To the In Vitro Diagnostics Market
Figure 54 Middle East: In Vitro Diagnostics Market Snapshot
Figure 55 Saudi Arabia: Number of People Aged 65 Years and Above, 2017–2021 (Thousand)
Figure 56 Africa: In Vitro Diagnostics Market Snapshot
Figure 57 South Africa: Number of People (All Ages) Living With HIV, 2010–2020 (Million)
Figure 58 South Africa: Number of People With Diabetes, 2000–2045 (Thousand)
Figure 59 Key Growth Strategies Adopted by Leading Players (2019–2023)
Figure 60 Competitive Dashboard: Global In Vitro Diagnostics Market
Figure 61 Global In Vitro Diagnostics Market Competitive Benchmarking, by Offering
Figure 62 Market Share Analysis: Global In Vitro Diagnostics Market (2022)
Figure 63 Abbott Laboratories: Financial Overview (2021)
Figure 64 Becton, Dickinson and Company: Financial Overview (2022)
Figure 65 biom?rieux S.A.: Financial Overview (2021)
Figure 66 Danaher Corporation: Financial Overview (2021)
Figure 67 F. Hoffman-La Roche Ltd: Financial Overview (2021)
Figure 68 Qiagen N.V.: Financial Overview (2021)
Figure 69 Siemens Healthineers AG (A Subsidiary of Siemens AG): Financial Overview (2022)
Figure 70 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 71 Bio-Rad Laboratories: Financial Overview (2021)
Figure 72 Illumina, Inc.: Financial Overview (2021)
Figure 73 Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Overview (2021)
Figure 74 QuidelOrtho Corporation; Financial Overview (2021)
Figure 75 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 76 DiaSorin S.p.A: Financial Overview (2021)
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 8 Global in Vitro Diagnostic (IVD) Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global in Vitro Diagnostic Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global in Vitro Diagnostic Market, by Diagnostic Approach, 2023 Vs. 2030 (USD Million)
Figure 11 Global in Vitro Diagnostic Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Global IVD Market, by Geography
Figure 13 Factors Affecting Market Growth
Figure 14 U.S.: Medical and Health R&D Expenditure, 2016–2020 (USD Billion)
Figure 15 Global Biopharmaceutical R&D Expenditure, 2016–2028 (USD Billion)
Figure 16 USFDA Regulatory Pathways for IVD Kits
Figure 17 EU Regulatory Pathway - IVDR 2017/746
Figure 18 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
Figure 19 Global In Vitro Diagnostics (IVD) Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 20 Global in Vitro Diagnostic Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 21 Global In Vitro Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 22 U.S.: Estimated Acute Hepatitis C Cases, 2011–2020
Figure 23 Estimated Number of New Cancer Cases, by Region, 2020–2040 (Million)
Figure 24 Total Number of Accredited Testing Laboratories (ISO/IEC 17025), 2016–2020
Figure 25 Prevalence of Diabetes Across the World (In Million)
Figure 26 Global In Vitro Diagnostics Market, by Diagnostic Approach 2023 Vs. 2030 (USD Million)
Figure 27 Benefits of Laboratory Testing Approach
Figure 28 Benefits of the Point-of-Care Testing Approach
Figure 29 Global In Vitro Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 30 Global In Vitro Diagnostics Market, by Region, 2023 Vs. 2030 (USD Million)
Figure 31 North America: Number of People Aged 65 Years and Above, 2015–2021 (Million)
Figure 32 North America: Per Capita Health Expenditure (USD), 2017–2021
Figure 33 North America: In Vitro Diagnostics Market Snapshot
Figure 34 Canada: Number of People Aged 65 and Above, 2018–2022 (Million)
Figure 35 Europe: Number of People Aged 65 and Above (In Million) (2015–2021)
Figure 36 Europe: In Vitro Diagnostics Market Snapshot
Figure 37 France: Percentage of Population Aged 65 Years and Above (2016–2021)
Figure 38 France: Prevalence of Chronic Diseases in People Aged 65 and Above (2020)
Figure 39 U.K: Number of Cancer Cases, 2010–2030 (Million)
Figure 40 U.K.: Number of Diabetes and Urogenital, Blood, and Endocrine Disease Cases – DALYS (Disability-Adjusted Life Years), 2017–2020 (Thousand)
Figure 41 U.K.: Number of People Diagnosed With Sexually Transmitted Infections, 2018–2020 (Thousand)
Figure 42 Prevalence of HAI in Healthcare-Associated Infections in Acute-Care Wards (2016–2021)
Figure 43 Italy: Ovarian Cancer Cases Diagnosed (2018–2020)
Figure 44 Number of HIV Tests Performed in Catalonia (Spain) (2014–2021)
Figure 45 Switzerland: Number of New Cancer Cases (2020–2040)
Figure 46 Switzerland: Number of People Aged 65 Years and Above (2017–2021)
Figure 47 Asia-Pacific: In Vitro Diagnostics Market Snapshot
Figure 48 Japan: Percentage Share of the Geriatric Population (Aged 65 Years And Above) (2015–2022)
Figure 49 Japan: New Cancer Cases Reported (2020–2040)
Figure 50 China: Independent Medical Laboratories Market, 2015–2021 (USD Million)
Figure 51 India: Number of People Aged 65 Years and Above, 2017–2021 (Million)
Figure 52 Latin America: In Vitro Diagnostics Market Snapshot
Figure 53 Brazil: Challenges To the In Vitro Diagnostics Market
Figure 54 Middle East: In Vitro Diagnostics Market Snapshot
Figure 55 Saudi Arabia: Number of People Aged 65 Years and Above, 2017–2021 (Thousand)
Figure 56 Africa: In Vitro Diagnostics Market Snapshot
Figure 57 South Africa: Number of People (All Ages) Living With HIV, 2010–2020 (Million)
Figure 58 South Africa: Number of People With Diabetes, 2000–2045 (Thousand)
Figure 59 Key Growth Strategies Adopted by Leading Players (2019–2023)
Figure 60 Competitive Dashboard: Global In Vitro Diagnostics Market
Figure 61 Global In Vitro Diagnostics Market Competitive Benchmarking, by Offering
Figure 62 Market Share Analysis: Global In Vitro Diagnostics Market (2022)
Figure 63 Abbott Laboratories: Financial Overview (2021)
Figure 64 Becton, Dickinson and Company: Financial Overview (2022)
Figure 65 biom?rieux S.A.: Financial Overview (2021)
Figure 66 Danaher Corporation: Financial Overview (2021)
Figure 67 F. Hoffman-La Roche Ltd: Financial Overview (2021)
Figure 68 Qiagen N.V.: Financial Overview (2021)
Figure 69 Siemens Healthineers AG (A Subsidiary of Siemens AG): Financial Overview (2022)
Figure 70 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 71 Bio-Rad Laboratories: Financial Overview (2021)
Figure 72 Illumina, Inc.: Financial Overview (2021)
Figure 73 Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Overview (2021)
Figure 74 QuidelOrtho Corporation; Financial Overview (2021)
Figure 75 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 76 DiaSorin S.p.A: Financial Overview (2021)
